Similarly, when the risk scores are combined with tumor mutation burden (TMB), a similar trend towards improving the prediction of patient immune therapy response was observed, but it did not reach statistical significance ( Figure 8 N).
← all excerpts
Identification and Validation of Tumor Microenvironment-Associated Signature in Clear-Cell Renal Cell Carcinoma through Integration of DNA Methylation and Gene Expression.
1
—
—